Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients. / Nielsen, R.; Wiggers, Henrik; Halbirk, Mads; Bøtker, H; Holst, Jens Juul; Schmitz, Ole; Frandsen, Egon Randa; Nielsen, S; Møller, N; Nørrelund, Helene.
In: Experimental and Clinical Endocrinology and Diabetes, Vol. 120, No. 5, 2012, p. 266-72.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients
AU - Nielsen, R.
AU - Wiggers, Henrik
AU - Halbirk, Mads
AU - Bøtker, H
AU - Holst, Jens Juul
AU - Schmitz, Ole
AU - Frandsen, Egon Randa
AU - Nielsen, S
AU - Møller, N
AU - Nørrelund, Helene
N1 - © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.
PY - 2012
Y1 - 2012
N2 - We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AB - We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
U2 - 10.1055/s-0032-1304605
DO - 10.1055/s-0032-1304605
M3 - Journal article
C2 - 22421983
VL - 120
SP - 266
EP - 272
JO - Experimental and Clinical Endocrinology and Diabetes
JF - Experimental and Clinical Endocrinology and Diabetes
SN - 0947-7349
IS - 5
ER -
ID: 38431407